 |
|
|
| |
Overall Safety Profile of Boceprevir Plus Peginterferon alfa-2a/Ribavirin in Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-9 2011 SF
S. Flamm1, E. Lawitz2, I. Jacobson3, M. Bourliere4, C. Hezode5, J. Vierling6, C. Niederau7, M. Sherman8, B. Bacon9, L. D. Pedicone10, V. Goteti10, M. Burroughs10, C. Brass10, J. Albrecht10, and F. Poordad11
1Northwestern Feinberg School of Medicine, Chicago, IL; 2Alamo Medical Research, San Antonio, TX; 3Weill Cornell Medical College, New York, NY; 4Fondation Hopital Saint Joseph, Marseille, France; 5A.P.H. Paris, Hopital Henri Mondor, Creteil Cedex, France; 6Baylor College of Medicine, Houston, TX; 7St. Josef-Hospital Oberhausen, Oberhausen, Germany; 8Toronto General Hospital, Toronto, Canada; 9Saint Louis University School of Medicine, St. Louis, MO; 10Merck Sharp & Dohme Corp., Whitehouse Station, NJ; 11Cedars-Sinai Medical Center, Los Angeles, CA
|
| |
|
|
|
|
|
